The therapeutic problem of proliferative diabetic retinopathy

Targeting somatostatin receptors

M. I. Davis, S. H. Wilson, M. B. Grant

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Clinical management of proliferative diabetic retinopathy has changed very little in the last 5 decades, relying primarily on laser ablation of the retinal vasculature. Several lines of clinical and experimental evidence suggest that somatostatin analogues may be efficacious in inhibiting neovascularization associated with proliferative retinopathy but the mechanism of action for these compounds is unclear. Inhibition of growth hormone secretion and the subsequent suppression of insulin-like growth factor 1 (IGF-1) production by somatostatin has been suggested as the mechanism of action, however, in vitro studies suggest that somatostatin analogues suppress endothelial cell growth through a direct, somatostatin receptor-mediated inhibition of pro-survival signaling pathways. The advent of a new generation of modified peptide and peptidomimetic somatostatin analogues has allowed investigators to more carefully define the receptor subtypes responsible for somatostatin-induced endothelial cell death and may eventually lead to the clinical development of somatostatin analogues that can reduce endothelial cell proliferation, independent of suppression of circulating hormone levels.

Original languageEnglish (US)
Pages (from-to)295-299
Number of pages5
JournalHormone and Metabolic Research
Volume33
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Somatostatin Receptors
Diabetic Retinopathy
Somatostatin
Endothelial cells
Endothelial Cells
Therapeutics
Peptidomimetics
Cell proliferation
Cell growth
Laser Therapy
Somatomedins
Cell death
Laser ablation
Growth Hormone
Cell Death
Research Personnel
Cell Proliferation
Hormones
Peptides
Growth

Keywords

  • Angiogenesis
  • Apoptosis
  • Diabetic Retinopathy
  • Growth Hormone
  • Insulin-Like Growth Factor
  • Octreotide
  • Somatostatin

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

The therapeutic problem of proliferative diabetic retinopathy : Targeting somatostatin receptors. / Davis, M. I.; Wilson, S. H.; Grant, M. B.

In: Hormone and Metabolic Research, Vol. 33, No. 5, 2001, p. 295-299.

Research output: Contribution to journalArticle

Davis, M. I. ; Wilson, S. H. ; Grant, M. B. / The therapeutic problem of proliferative diabetic retinopathy : Targeting somatostatin receptors. In: Hormone and Metabolic Research. 2001 ; Vol. 33, No. 5. pp. 295-299.
@article{93f1406ebe42470ea90a781ab297fa0c,
title = "The therapeutic problem of proliferative diabetic retinopathy: Targeting somatostatin receptors",
abstract = "Clinical management of proliferative diabetic retinopathy has changed very little in the last 5 decades, relying primarily on laser ablation of the retinal vasculature. Several lines of clinical and experimental evidence suggest that somatostatin analogues may be efficacious in inhibiting neovascularization associated with proliferative retinopathy but the mechanism of action for these compounds is unclear. Inhibition of growth hormone secretion and the subsequent suppression of insulin-like growth factor 1 (IGF-1) production by somatostatin has been suggested as the mechanism of action, however, in vitro studies suggest that somatostatin analogues suppress endothelial cell growth through a direct, somatostatin receptor-mediated inhibition of pro-survival signaling pathways. The advent of a new generation of modified peptide and peptidomimetic somatostatin analogues has allowed investigators to more carefully define the receptor subtypes responsible for somatostatin-induced endothelial cell death and may eventually lead to the clinical development of somatostatin analogues that can reduce endothelial cell proliferation, independent of suppression of circulating hormone levels.",
keywords = "Angiogenesis, Apoptosis, Diabetic Retinopathy, Growth Hormone, Insulin-Like Growth Factor, Octreotide, Somatostatin",
author = "Davis, {M. I.} and Wilson, {S. H.} and Grant, {M. B.}",
year = "2001",
doi = "10.1055/s-2001-15286",
language = "English (US)",
volume = "33",
pages = "295--299",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "5",

}

TY - JOUR

T1 - The therapeutic problem of proliferative diabetic retinopathy

T2 - Targeting somatostatin receptors

AU - Davis, M. I.

AU - Wilson, S. H.

AU - Grant, M. B.

PY - 2001

Y1 - 2001

N2 - Clinical management of proliferative diabetic retinopathy has changed very little in the last 5 decades, relying primarily on laser ablation of the retinal vasculature. Several lines of clinical and experimental evidence suggest that somatostatin analogues may be efficacious in inhibiting neovascularization associated with proliferative retinopathy but the mechanism of action for these compounds is unclear. Inhibition of growth hormone secretion and the subsequent suppression of insulin-like growth factor 1 (IGF-1) production by somatostatin has been suggested as the mechanism of action, however, in vitro studies suggest that somatostatin analogues suppress endothelial cell growth through a direct, somatostatin receptor-mediated inhibition of pro-survival signaling pathways. The advent of a new generation of modified peptide and peptidomimetic somatostatin analogues has allowed investigators to more carefully define the receptor subtypes responsible for somatostatin-induced endothelial cell death and may eventually lead to the clinical development of somatostatin analogues that can reduce endothelial cell proliferation, independent of suppression of circulating hormone levels.

AB - Clinical management of proliferative diabetic retinopathy has changed very little in the last 5 decades, relying primarily on laser ablation of the retinal vasculature. Several lines of clinical and experimental evidence suggest that somatostatin analogues may be efficacious in inhibiting neovascularization associated with proliferative retinopathy but the mechanism of action for these compounds is unclear. Inhibition of growth hormone secretion and the subsequent suppression of insulin-like growth factor 1 (IGF-1) production by somatostatin has been suggested as the mechanism of action, however, in vitro studies suggest that somatostatin analogues suppress endothelial cell growth through a direct, somatostatin receptor-mediated inhibition of pro-survival signaling pathways. The advent of a new generation of modified peptide and peptidomimetic somatostatin analogues has allowed investigators to more carefully define the receptor subtypes responsible for somatostatin-induced endothelial cell death and may eventually lead to the clinical development of somatostatin analogues that can reduce endothelial cell proliferation, independent of suppression of circulating hormone levels.

KW - Angiogenesis

KW - Apoptosis

KW - Diabetic Retinopathy

KW - Growth Hormone

KW - Insulin-Like Growth Factor

KW - Octreotide

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0034955429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034955429&partnerID=8YFLogxK

U2 - 10.1055/s-2001-15286

DO - 10.1055/s-2001-15286

M3 - Article

VL - 33

SP - 295

EP - 299

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 5

ER -